Search for: "Boehringer Ingelheim Corporation"
Results 21 - 40
of 47
Sorted by Relevance
|
Sort by Date
30 Dec 2009, 3:44 am
In this event Panels partially dismiss complaints to the extent that they include additional unrelated respondents, as in Boehringer Ingelheim Pharma GmbH & Co. [read post]
1 Aug 2019, 8:30 am
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
11 Jul 2007, 11:22 am
Court of Appeal (Civil Division) Aziz v Aziz & Ors Rev 1 [2007] EWCA Civ 712 (11 July 2007) Masri v Consolidated Contractors International Company SAL & Anor [2007] EWCA Civ 688 (11 July 2007) Adelson & Anor v Associated Newspapers Ltd. [2007] EWCA Civ 701 (09 July 2007) MM, R (on the application of) v Secretary of State for the Home Department [2007] EWCA Civ 687 (06 July 2007) Togher v Revenue and Customs Prosecutions Office & Anor [2007] EWCA Civ 686 (05 July 2007)… [read post]
30 Jan 2020, 5:29 am
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
30 Jan 2020, 5:29 am
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
21 Apr 2021, 4:00 am
It is well established in trademark jurisprudence that the owner of a mark is not legally responsible for torts allegedly perpetrated by its user: Batten v Boehringer Ingelheim (Canada) Ltd., 2017 ONSC 53, at para. 153. [read post]
21 Jan 2015, 3:02 pm
But as we’ve blogged, thousands of patients on Pradaxa, which was the first of the three to be approved by the FDA, have been harmed by uncontrolled bleeding, and its manufacturer, Boehringer Ingelheim, has been fined for covering up adverse outcomes in its research for the drug. [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
9 Oct 2012, 1:41 pm
One major victory was in 2012, the pharmacy won a settlement with Boehringer Ingelheim, a large pharmaceutical company, for $289 million for overcharging government health programs for various drugs. [read post]
26 Aug 2009, 6:12 am
The Corporate Gold Rush to Patent Your Genes’ perpetuates popular misperceptions surrounding gene patents (Holman's Biotech IP Blog) Australian pharmaceutical patent term extension for patches and implants: N V Organon; LTS Lohmann Therapie-Systeme AG and Schwarz Pharma Limited (Patent Baristas) China: Obama Administration and compulsory licensing in China (China Hearsay) China: Forty-two of Simcere’s generic drugs enter China’s Essential Drug List… [read post]
4 Sep 2018, 7:00 am
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
4 Sep 2018, 7:00 am
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
31 Jan 2013, 12:57 pm
The plaintiffs brought a product liability claim against Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
9 Aug 2011, 4:30 am
Boehringer Ingelheim Pharma., Inc., C.A. [read post]
23 Sep 2014, 4:38 am
BootsDeckers Outdoor Corporation v J.C. [read post]
19 Oct 2018, 2:17 am
Our largest and most innovative pharmaceutical company, Boehringer Ingelheim, has a German "mother“ if I may call it that, which accordingly means that its patent division is in Germany as well. [read post]
19 Sep 2014, 5:50 pm
Michael Kompter (Senior Patent Counsel, IP Awareness and Enforcement, Boehringer Ingelheim, Germany) considered the issue of privilege from the standpoint of a civil law jurisdiction, as well as providing an in-house counsel’s perspective. [read post]
17 Oct 2007, 8:59 am
And now the tipping point is in sight as more law departments and law firms inch towards greater use of evaluations and assessments-- and trumpet the benefits.General Counsel Scott Terrillion, of Boehringer Ingelheim Pharmaceuticals Inc, uses an "evaluative selection method" to find the best attorneys for his company, with diversity being a natural consequence. [read post]
3 Apr 2014, 5:00 am
and because sales reps are a mobile workforce without benefit of offices within corporate headquarters. [read post]
5 Jul 2008, 11:05 am
: (Intellectual Property Watch), Why compulsory licenses are bad: a look at the sausage making process: (Techdirt) More on ACTA: (LawFont.com) Global - Trade Marks / Domain Names / Brands Brand Finance 500: the annual report on the world’s most valuable brands: (IP finance), Gretchen Olive’s ‘10 steps to an effective domain name policy’: (IPwar’s), ICANN approves GNSO proposals imposing financial penalty on registrars who engage in excessive domain… [read post]
